SARS-CoV-2

Latest news

21.06.2022
Particularly fast: The new EURORealTime SARS-CoV-2 Fast enables highly specific and sensitive direct detection of SARS-CoV-2 by means of reverse-transcriptase real-time PCR within about 45 minutes.

• EURORealTime SARS-CoV-2 Fast Product

13.06.2022
NEW! Two test systems complement the product portfolio for COVID-19 serology: The Anti-SARS-CoV-2 RBD ChLIA (IgG) and the Anti-SARS-CoV-2 Omicron ELISA (IgG) enable quantification of anti-SARS-CoV-2 IgG antibodies.

• Anti-SARS-CoV-2 RBD ChLIA (IgG) Product
• Anti-SARS-CoV-2 Omicron ELISA (IgG) Product

Press release

24.01.2022
Update on the Omicron virus variant and the Quan-T-Cell: We do not yet have the experimental data to make statements on the possible effects of the Omicron variant on our Quan-T-Cell for the detection of SARS-CoV-2-specific T-cell activity. However, a variety of publications already confirm that T-cell reactivity against virus variants including Omicron is very stable and that it offers a certain level of variant-independent immune protection.

Read more here:

• Redd et al. Preprint bioRxiv. 2021
• Naranbhai et al. Preprint medRxiv. 2022
• Keeton et al. Preprint medRxiv. 2021
• Pfizer. Press release as of December 8 2021. Pfizer and BioNTech Provide Update on Omicron Variant | Pfizer

21.01.2022
Detection of antibody response after vaccination: All COVID-19 vaccines currently used and approved in the EU are based on the wild type version of the spike protein (Wuhan-Hu-1). This means that antibodies formed after such vaccination can definitely be detected by the S1-based antibody assays from EUROIMMUN.

Using antibody tests based on the nucleocapsid protein (NCP), antibody reactions after vaccination can be distinguished after those formed after a contact with SARS-CoV-2 (does not apply for the use of vaccines which also contain an N component). A positive result in the Anti-SARS-CoV-2 NCP ELISA (IgG) indicates a past contact with the pathogen. However, even with a negative result a past SARS-CoV-2 infection cannot be excluded.

With our cooperation partner Homed-IQ, EUROIMMUN offers companies and individuals a simple and well-organised option for vaccination titer determination. You would like to learn more?
Read the whole article here.

20.01.2022
Update on the Omicron virus variant and S1-based antibody detection: We do not yet have the experimental data to make statements on the possible effects of the Omicron variant on our serological test systems for the detection of antibodies against the S1 domain.

The acquisition of the serum samples required from patients positive for the Omicron variant but immunologically naive to other SARS-CoV-2 variants (i.e. who have never been in contact with the wild type form or other variants and were not vaccinated against SARS-CoV-2) proves very challenging.

Although it cannot generally be excluded that an infection with the SARS-CoV-2 variant Omicron leads to formation of antibodies which are not or only poorly detectable by the S1 wild type isolate (Wuhan-Hu-1) used by us, our in silico analyses do show that the amino acid sequence of the S1 domain and the RBD within the S1 domain of the Omicron variant and the wild type are highly homologous. Therefore, we do not expect a negative effect of the Omicron mutations on the performance of our test systems for antibodies against the S1 domain at this stage.
More information in our FAQ

02.12.2021
Information on Omicron variant: According to in silico analysis, the new SARS-CoV-2 variant, called Omicron, is expected to be reliably detected by our EURORealTime SARS-CoV-2 and EURORealTime SARS-CoV-2/Influenza A/B tests systems. This also applies to the virus variants Alpha, Beta, Gamma, Delta, Lambda and Mu.

At this early stage it is not yet possible to make a statement about the possible effects of the Omicron variant on the performance of the EUROIMMUN antibody test systems or the interferon-gamma release assay Quan-T-Cell SARS-CoV-2.

EUROIMMUN carefully follows all reports and official information on the new SARS-CoV-2 variant from sources like the ECDC, WHO or FDA and immediately investigates possible effects on the test systems as soon as corresponding data is available.
More information in our FAQ

25.10.2021
Efficient combination: one test for COVID-19 and flu - By using the EURORealTime SARS-CoV-2/Influenza A/B it is possible to keep an eye not only on the spread of COVID-19 but also of the upcoming flu in an efficient and resource-saving way.
Product
Product flyer

02.09.2021
NOW! with CE mark! The interferon-gamma release assay from EUROIMMUN is already established in research and allows determination of the activity of SARS-CoV-2-reactive T cells to support the evaluation of the cellular immune response after infection or vaccination.
Product